Premium Group Company Ltd (PK) (PMMFF) News

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE...

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...

GeoVax to Present at the 36th Annual Roth Conference

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1...

Form 4 - Statement of changes in beneficial ownership of securities

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire...

GeoVax to Present at the 2024 BIO CEO & Investor Conference

ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...